Corilagin
Cat. No. :YN251489
CAS No. :23094-69-1
Pack size
price
inventory
5mg
Enquiry
Enquiry
10mg
Enquiry
Enquiry
25mg
Enquiry
Enquiry
50mg
Enquiry
Enquiry
86-020-82000279
sales@ubiochem.com
order@ubiochem.com| Product Name: | Corilagin |
| CAS NO.: | 23094-69-1 |
| Chemical Name: | |
| Synonyms: | |
| Molecular Weight: | 634.45 |
| Molecular Formula: | C₂₇H₂₂O₁₈ |
| SMILES: | OC1=C(C2=C(C(OC[C@H]3O[C@@H](OC(C4=CC(O)=C(O)C(O)=C4)=O)[C@@H](O)[C@@H]([C@H]3O)OC5=O)=O)C=C(O)C(O)=C2O)C5=CC(O)=C1O |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Transportation: | Room temperature in continental US; may vary elsewhere. |
| Description: | Corilagin has anti-inflammatory activity. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro. Corilagin can enhance the cytotoxicity of both cisplatin and doxorubicin on the Hep3B hepatoma cells. Corilagin has antiviral activity, reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 μg/mL, respectively. Corilagin shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways. Corilagin has antifibrotics property and is potentiated in treating idiopathic pulmonary fibrosis(IPF), attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-κB and TGF-β1 signaling. Corilagin can remarkably reduce the minimum inhibitory concentration (MIC) of beta-lactams in methicillin-resistant Staphylococcus aureus(MRSA), it suppresses the activity of beta-lactamase to some extent. 8. Corilagin has antioxidant activity, it is protective against GalN/LPS-induced liver injury through suppression of oxidative stress and apoptosis. 9. Corilagin is effective in inhibiting the progress of atherosclerosis by alleviating oxidation injury or by inhibiting oxidized low-density lipoprotein (ox-LDL)-induced vascular smooth muscular cells (VSMC) proliferation, which may be promising mechanisms for treating atherosclerosis. 10. Corilagin possesses the ability to lower blood pressure through the reduction of noradrenaline release and (or) direct vasorelaxation. |
| IC50&Target: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: | |
| References: |
TELL : +86-020-82000279
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.
